Active	Status	Sponsor type	Region	Phase	Filter
10 Active 1 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhang, Lili
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes	Recruiting	3	424	RoW	Victoza®., Metformin Hydrochloride, TQZ2451	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Type 2 Diabetes	12/21	12/21
RECAM, NCT04807348: Chiglitazar Added to Metformin for Type 2 Diabetes	Completed	3	533	RoW	Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage	Chipscreen Biosciences, Ltd.	Type 2 Diabetes	02/23	02/23
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer	Active, not recruiting	3	274	RoW	BPI-16350, placebo, Fulvestrant	Betta Pharmaceuticals Co., Ltd.	Breast Cancer	12/23	07/25
NCT06633783: A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®	Not yet recruiting	3	370	RoW	Semaglutide	Hangzhou Jiuyuan Gene Engineering Co. Ltd.,	Obesity	05/26	10/26